New Features information at Pharmaceutical Technology New and updated information from Features listed on en-us New Features information at Pharmaceutical Technology Pharma Technology Focus – Issue 55 In this issue: India’s new drug pricing policy, bringing transparency to pharma industry payments, a UK innovation centre enabling new means of drug discovery, how artificial intelligence is being used in drug development, and more. Wed, 18 Jan 2017 15:21:00 GMT Pharma payments to doctors: seeking transparency A Europe-wide initiative bringing transparency to pharma industry payments to healthcare professionals and organisations has prompted a spirited debate across the continent. Ireland is no exception, with critics questioning the €27.2m paid to public … Mon, 16 Jan 2017 00:00:00 GMT After the cure: addressing side effects in childhood cancer patients While survival rates for childhood cancer have increased, many survivors are blighted by health problems later in life. According to a new study, these ‘late effects’ seem to be no better for more recently treated patients than for those who were tre… Thu, 12 Jan 2017 00:00:00 GMT How does the NHS weigh the costs of HIV preventing drugs? In August, the High Court ruled that NHS England can fund the use of PrEP – effective but very expensive drugs that prevent HIV infection. But with the NHS appealing that decision, it is unclear whether PrEP will ever be commissioned. Abi Millar expl… Thu, 12 Jan 2017 00:00:00 GMT India's drug price overhaul: a question of balance India’s drug pricing policy is set for an overhaul, but has the government struck the right balance between ensuring affordable access to medicines and creating a regulatory landscape that works for the industry? Elly Earls investigates. Mon, 09 Jan 2017 00:00:00 GMT Pay-for-delay: how far will companies go to protect market exclusivity? While some form of patent protection is clearly necessary, pay-for-delay agreements are more contentious. What happens when pharma companies pay large sums to prolong a patent and delay exposure to competition? Do patients suffer? Abi Millar investig… Tue, 03 Jan 2017 00:00:00 GMT 2016: The year's biggest Pharmaceutical Technology stories US FDA approved AstraZeneca's new indication of Faslodex (fulvestrant), WHO reported the mosquito-transmitted Zika virus is spreading explosively, while NHS England reconsidered its previously made decision not to fund the new HIV treatment. Pharmace… Tue, 03 Jan 2017 00:00:00 GMT Pharma Technology Focus – Issue 54 In this issue: Senator Bernie Sanders continues to rail against the pharma industry, why companies pay to prolong patents, a new genomic array helping fight disease in Africa, treating mononucleosis, a new era for ibuprofen, and more. Wed, 14 Dec 2016 14:24:00 GMT Debating the value of targeted lung cancer treatments US industry group Pharmaceutical Research and Manufacturers of America (PhRMA) has criticised an evidence report by the Institute for Clinical and Economic Review (ICER), which puts a low value on targeted treatments and immunotherapy for non-small c… Wed, 14 Dec 2016 00:00:00 GMT Tackling false trial data in China China makes huge contributions to global pharma manufacturing and drug discovery, but there is a problem at the heart of Chinese research that threatens the integrity of the sector: according to a government investigation, more than 80% of Chinese cl… Mon, 12 Dec 2016 00:00:00 GMT Genomic array could unlock war against diseases in Africa A new genomic array will provide the foundation for more detailed research than ever before into the genetic and environmental causes of common diseases in Africa. Elly Earls finds out from two of the project’s key players how their affordable innova… Mon, 12 Dec 2016 00:00:00 GMT Ibuprofen: could this ubiquitous drug be entering a whole new era? Ibuprofen could soon be entering a new era, thanks to breakthrough research on the cardiovascular effects of one formulation of the drug. With one eye on the future, we look back at the medication’s more than 50 year history, to see how it’s become j… Thu, 08 Dec 2016 00:00:00 GMT November's top stories: Patheon to buy API facility, UK NICE approved Celgene’s drug Patheon agreed to acquire a new API manufacturing facility in the US, and UK NICE approved Celgene’s Imnovid drug for use in relapsed myeloma patients. wraps up the key headlines from November. Wed, 07 Dec 2016 00:00:00 GMT Pfizer’s big antibiotic buyout: a sign of things to come? Pfizer’s acquisition of AstraZeneca’s antibiotics unit will certainly strengthen its anti-infectives portfolio, but is it also a precursor to bigger moves from the US drug maker? Elly Earls reports. Mon, 05 Dec 2016 00:00:00 GMT Ketamine: taking aim at depression Since the turn of the millennium, researchers have been investigating ketamine as a potential treatment for major depression. Today, with the largest trial to date underway and several ketamine-like drugs under development, we are moving closer to un… Thu, 01 Dec 2016 00:00:00 GMT Pharma Technology Focus – Issue 53 In this issue: Pfizer’s acquisition of AstraZeneca’s antibiotics unit, new ideas to tackle antimicrobial resistance, vaccines to look out for in 2017, targeting Tourette syndrome, using ketamine to treat depression, and more. Thu, 17 Nov 2016 16:41:00 GMT Bernie vs. Big Pharma Vermont Senator Bernie Sanders has continued to rail against pharmaceutical industry pricing since losing the Democratic nomination to Hillary Clinton. With Sanders’s presidential ambitions scuppered, should the pharma industry fear the fury of a pol… Thu, 17 Nov 2016 00:00:00 GMT October's top stories: GSK shingles vaccine, Pfizer’s Inflectra injection in US GSK submitted a biologics licence application to the FDA for its candidate shingles vaccine Shingrix, Pfizer announced its introduction of Inflectra (infliximab-dyyb) for injection in the US and Teva agreed to sell Actavis Generics assets and operati… Thu, 10 Nov 2016 00:00:00 GMT Antibiotic resistance: the race for the prize The Longitude Prize has set the standard for competitions looking for disruptive new ideas to tackle the growing antimicrobial resistance crisis. Nesta’s Longitude Prize lead Tamar Ghosh discusses the competition process, now approaching the end of i… Tue, 08 Nov 2016 00:00:00 GMT Open debate: is it ever justified to withhold clinical trial data? The debate over open access to clinical trial data is not a new one, and in August two editorials in the New England Journal of Medicine drew the battle lines once more. The big question: does it strengthen academic research, or lead investigators vu… Thu, 03 Nov 2016 00:00:00 GMT